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INTRODUCTION
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•	76-year-old female with no medical history presented with right ear pain and hearing loss
•	Pembrolizumab (PBM) is a monoclonal antibody
targeted against program cell death-1 (PD-1)
proteins on cell surfaces, thus inhibiting their
interaction and allowing the body’s immune
1
system to recognize and destroy malignant cells
•	PBM was initially FDA approved in 2014 for
the treatment of advanced melanoma however
as of May 2017 has been approved for the
initial treatment of any solid metastatic or non2
resectable tumors with specific genetic mutations
•	Common side effects of this medication fatigue,
2
pruritus, anorexia, fever, and diarrhea
			 −	However, serious side effects such as autoimmune
pneumonitis, hepatitis, colitis, and pancreatitis
have been reported as the molecular “brakes” are
2
removed from the immune system

DISCUSSION

CASE REPORT
•	Head CT and MRI revealed mixed lytic and sclerotic temporal and maxillary bone lesions suggestive of a neoplastic
process
•	Surgical biopsy of the maxillary sinus diagnosed adenoid cystic carcinoma. PET scan initially negative for
metastatic disease
•	She underwent right maxillary sinus resection followed by adjunctive radiotherapy
•	Serial imaging 3 years later suggested reoccurrence within her right orbit which was confirmed by biopsy
•	Rather undergo repeat surgery, she was enrolled in a clinical trial with PBM
•	Following her 4th dose (3rd month) she complained of abdominal pain. CT noted intra- and extra-hepatic biliary
dilatation despite normal chemistries.
•	EUS demonstrated 3.2 x 2.5cm mass within the pancreatic head (Figure 1) with FNA biopsies consistent with
moderately differentiated adenocarcinoma which was not pathologically associated with her head and neck cancer.

•	PBM is a novel immunotherapy agent which has gained significant
interest with recent FDA approval for the treatment of various
malignancies
•	Presented is a case in which a patient developed a pancreatic
malignancy while being treated with PBM for her adenoid cystic
carcinoma
•	The incidence of pancreatic cancer among patients treated with
PBM is unclear
•	However given the recent FDA approval of PBM in solid tumors
(including pancreatic malignancies), this may ultimately be a
unfortunate coincidence
•	More data is required to identify the long-term risks of PBM,
specifically the incidence of new onset malignancies while on
therapy

•	She currently continues to undergo immunotherapy treatment
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Figure 1: EUS of the pancreatic head demonstrating a large hypoechoic mass.

